Benjamín W. Van Tassell|Nayef Abouzaki|Claudia Oddi Erdle|Salvatore Carbone|Cory Trankle|Ryan Melchior|Jeremy Turlington|Clinton J. Thurber|Sanah Christopher|Dave L. Dixon|Daniel T Fronk|Christopher Thomas|Scott W. Rose|Leo F. Buckley|Charles A. Dinarello|Giuseppe Biondi?Zoccai|Antonio Abbate
Interleukin-1 Blockade in Acute Decompensated Heart Failure
Istituto Neurologico Mediterraneo|Virginia Commonwealth University
heart failure inflammatory disease patients acute decompensated heart failure adhf exhibit significant inflammatory activity admission hypothesized interleukin1 blockade anakinra kineret swedish orphan biovitrum would quench acute inflammatory response patients adhfwe randomized 30 patients adhf reduced left ventricular ejection fraction 40 elevated c reactive protein crp levels 5 mgl either anakinra 100 mg twice daily 3 days followed daily 11 days matching placebo 11 double blinded fashion measured daily crp plasma levels using highsensitivity assay hospitalization 14 days evaluated areaunderthecurve interval changes deltatreatment anakinra well tolerated 72 hours anakinra reduced crp 61 versus baseline compared 6 reduction among patients receiving placebo p 0004 anakinra vs placebointerleukin1 blockade anakinra reduces systemic inflammatory response patients adhf studies warranted determine whether antiinflammatory effect translates improved clinical outcomes